Can I Take Vitamin B6 with Vyleesi (Bremelanotide)?

What Is Vyleesi and How Does It Work?

Vyleesi (bremelanotide) is the only FDA-approved on-demand injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin receptors, particularly MC1R and MC4R, in the central nervous system to modulate desire-related neural pathways. The drug is injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity.

Approval and Indication

The FDA approved bremelanotide in June 2019 under NDA 210557 specifically for acquired, generalized HSDD in premenopausal women. HSDD is defined as low sexual desire that causes marked distress or interpersonal difficulty and is not explained by a co-existing medical or psychiatric condition or relationship problems alone.

Pharmacokinetics at a Glance

Understanding the drug's pharmacokinetics is the starting point for evaluating any supplement interaction. Bremelanotide reaches peak plasma concentration (Cmax) roughly 1 hour after subcutaneous injection. Its half-life is approximately 2.7 hours. Metabolism occurs primarily through hydrolysis of the amide bonds rather than through the cytochrome P450 (CYP) enzyme system [1]. This matters because most supplement-drug interactions involving vitamins happen through CYP3A4, CYP2D6, or P-glycoprotein pathways. Bremelanotide largely bypasses those routes.

Protein binding is approximately 21%, which is relatively low and reduces the likelihood of displacement-type interactions with co-administered supplements.

Does Vitamin B6 Interact with Vyleesi Pharmacokinetically?

No pharmacokinetic interaction between vitamin B6 (pyridoxine, pyridoxal, or pyridoxal-5-phosphate) and bremelanotide has been identified in prescribing literature, FDA labeling, or peer-reviewed pharmacology studies. The reason is mechanistic: B6 is not a meaningful inhibitor or inducer of the enzymes bremelanotide relies on.

How Vitamin B6 Is Metabolized

Pyridoxine is absorbed in the small intestine and converted hepatically to the active coenzyme pyridoxal-5-phosphate (PLP). PLP is involved in transamination, decarboxylation, and neurotransmitter synthesis, including the production of serotonin, dopamine, and GABA [2]. B6 does not meaningfully inhibit CYP3A4, CYP2D6, or CYP2C19 at physiological or supplemental doses. It is not a P-glycoprotein modulator at standard concentrations.

Because bremelanotide is metabolized primarily by peptide hydrolysis rather than hepatic CYP enzymes, and because B6 does not affect hydrolytic pathways, there is no pharmacokinetic basis for a clinically meaningful interaction.

What the FDA Label Actually Says

Vyleesi's prescribing information lists naltrexone as a drug with a documented interaction (bremelanotide reduces naltrexone absorption by approximately 35% in pharmacokinetic studies) [1]. Vitamins and mineral supplements are not mentioned in the interaction section of the label. The label does note that high-fat meals slowed bremelanotide absorption slightly but did not change overall exposure, indicating the drug is relatively insensitive to co-ingested substances.

Does Vitamin B6 Interact with Vyleesi Pharmacodynamically?

A pharmacodynamic interaction would occur if B6 either amplified or antagonized bremelanotide's effect on desire, blood pressure, or other physiological targets. No such interaction has been documented in clinical literature.

Melanocortin Receptors and B6

Bremelanotide's pharmacological target, the melanocortin receptor system (specifically MC4R in hypothalamic circuits), is not known to be directly modulated by pyridoxal-5-phosphate or any B6 vitamer. PLP is a cofactor in neurotransmitter synthesis, but there is no published evidence that adjusting B6 status changes MC4R sensitivity or bremelanotide's efficacy.

Nausea and B6: A Special Consideration

Nausea was the most commonly reported adverse effect in Vyleesi's phase 3 trials, occurring in approximately 40% of participants [3]. Some women and their clinicians reach for vitamin B6 to manage nausea, a practice with an established evidence base in pregnancy-related nausea. The FDA-approved combination of doxylamine and pyridoxine (Diclegis/Bonjesta) for morning sickness demonstrates that B6 is recognized as an antiemetic adjunct [4].

Using B6 to blunt Vyleesi-related nausea is a reasonable, though off-label, approach. Taking 10 to 25 mg of pyridoxine 30 to 60 minutes before a Vyleesi injection may reduce nausea severity, based on extrapolation from obstetric data. No randomized trial has tested this combination specifically, so the evidence is indirect. Discuss this strategy with your prescriber before trying it.

HealthRX Clinical Framework: Evaluating B6 Use Alongside Vyleesi

| Patient Scenario | B6 Dose in Use | Risk Level | Recommended Action | |---|---|---|---| | Standard multivitamin (1.3-2 mg B6) | <10 mg/day | Negligible | No action needed | | B-complex supplement | 10-50 mg/day | Very low | Safe; monitor for nausea improvement | | Standalone B6 for nausea | 10-25 mg/day | Very low | Discuss with prescriber; reasonable off-label use | | High-dose B6 for PMS | 100-200 mg/day | Low to moderate | Stay at or below 100 mg/day; monitor for tingling | | Megadose B6 | Above 200 mg/day | Moderate to high | Reduce dose; B6-induced neuropathy risk is independent of Vyleesi |

The Real Risk: High-Dose Vitamin B6 Neuropathy

The clinically significant concern with vitamin B6 is not its interaction with Vyleesi. It is the well-documented risk of peripheral neuropathy from chronic high-dose supplementation, a risk that exists regardless of what other medications you are taking.

Evidence from Clinical Literature

Sensory peripheral neuropathy from pyridoxine was first described in a landmark 1983 case series by Schaumburg et al., in which seven patients developed ataxia and severe sensory neuropathy after taking 2,000 to 6,000 mg of pyridoxine daily for months to years [5]. Later reports documented neuropathy at doses as low as 200 mg per day with prolonged use.

A 2023 systematic review published in the European Journal of Nutrition analyzed 30 case reports and found that the majority of B6 neuropathy cases involved daily intakes above 500 mg, though cases at 100 to 300 mg/day were reported with very long-term use (exceeding 12 months) [6].

NIH Tolerable Upper Intake Level

The NIH Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for vitamin B6 at 100 mg per day for adults, based on the risk of sensory neuropathy [2]. This ceiling applies regardless of concurrent medications. Staying at or below 100 mg per day is the key safety boundary.

Symptoms to Watch For

Early B6 neuropathy presents as bilateral tingling or numbness in the feet and hands, often described as a stocking-glove distribution. Gait instability may follow. Symptoms typically improve after stopping high-dose supplementation, though recovery can take months. Report any new neurological symptoms to your clinician promptly.

Bremelanotide's Adverse Effects: Does B6 Change Anything?

Vyleesi's known adverse effect profile includes nausea (approximately 40%), flushing (approximately 20%), injection-site bruising, headache, and transient increases in blood pressure averaging 6 mmHg systolic in the first 12 hours post-dose [3]. B6 has no known interaction with any of these mechanisms.

Blood Pressure Monitoring

The transient blood pressure increase with bremelanotide is clinically relevant for women with uncontrolled hypertension, which is listed as a contraindication in the label. Vitamin B6 does not meaningfully affect blood pressure at standard supplemental doses. One small trial (N=38) suggested high-dose B6 might reduce homocysteine, but the blood pressure effect was not statistically significant [7]. No additive blood pressure effect is expected.

Flushing and Melanocortin Receptors

Flushing from Vyleesi occurs because MC1R activation in peripheral melanocytes and vascular tissue causes local vasodilation. B6 does not interact with melanocortin receptors and does not amplify or suppress flushing.

What Clinical Guidelines Say About Supplement Use with HSDD Treatments

The International Society for the Study of Women's Sexual Health (ISSWSH) published a clinical practice guideline in 2021 recommending bremelanotide as a second-line pharmacological option for premenopausal women with HSDD when non-pharmacological approaches are insufficient [8]. The guideline does not restrict concurrent supplement use, but it does recommend a thorough medication and supplement review at baseline.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction similarly advises prescribers to evaluate all over-the-counter supplements at the point of prescribing any HSDD medication, not because interactions are common, but because baseline documentation supports safe monitoring [9].

"Clinicians should conduct a thorough assessment of prescription medications, over-the-counter drugs, and supplements as part of the initial evaluation of sexual dysfunction," states the Endocrine Society guideline (2019 Clinical Practice Guideline on Female Sexual Dysfunction, Section 3.2) [9].

Specific Populations and Special Scenarios

Women Taking B6 for PMS or PMDD

Vitamin B6 is sometimes self-prescribed for premenstrual syndrome (PMS) at doses of 50 to 200 mg per day. A 2016 Cochrane review found limited evidence that B6 up to 100 mg per day may reduce PMS symptoms compared to placebo, though trial quality was generally low [10]. Women using B6 for PMS who are also prescribed Vyleesi can generally continue B6 at or below 100 mg per day without concern about a drug-supplement interaction. The neuropathy risk warning applies at the same threshold regardless of Vyleesi use.

Women Taking a B-Complex

Most commercially available B-complex supplements contain 2 to 25 mg of B6 per serving. At these amounts, the cumulative daily B6 intake remains well below the NIH upper limit of 100 mg, even when a multivitamin is added. No dose adjustment or separation window is needed.

Timing of B6 and Vyleesi Doses

No pharmacokinetic data suggests that taking B6 at a different time of day from a Vyleesi injection changes anything meaningful. Bremelanotide's half-life of approximately 2.7 hours means it clears the system within 12 to 14 hours. B6 has a much longer tissue retention as PLP. There is no pharmacological rationale for a required dose-separation window between the two.

What to Tell Your Prescriber

Transparency about all supplements is good clinical practice, not because B6 and Vyleesi interact, but because your prescriber needs a complete picture of your health inputs to provide accurate guidance.

Specifically, disclose:

• The exact B6 dose you take (check every label, including multivitamins and B-complex products)
• How long you have been taking B6 at that dose
• Any neurological symptoms, even mild tingling, that predated Vyleesi use
• Any other supplements in your regimen, particularly those containing high-dose antioxidants or adaptogens, which have less studied interaction profiles with bremelanotide

If your daily B6 total across all products exceeds 100 mg, discuss whether the dose can be reduced before starting Vyleesi, not due to an interaction, but to eliminate the independent neuropathy risk before adding a new prescription.

Monitoring Checklist for Women Using Both

Routine clinical monitoring for women using Vyleesi does not specifically include B6 labs. Serum PLP testing is not ordered unless neuropathy symptoms are present. Practical monitoring steps include:

1. Check all supplement labels for B6 content before your first Vyleesi injection.
2. Keep total daily B6 at or below 100 mg.
3. Note any tingling, numbness, or balance changes at follow-up appointments.
4. If you experience nausea with Vyleesi, ask your clinician whether 10 to 25 mg of B6 taken 30 to 60 minutes prior to injection is appropriate for you.
5. Blood pressure should be checked before starting Vyleesi (the label advises against use in women with uncontrolled hypertension or cardiovascular disease); B6 does not affect this evaluation.

A follow-up call or message to your prescriber at 30 to 60 days after starting Vyleesi is appropriate to review how well the drug is working and whether any adverse effects, including nausea, are manageable.